Floatz logo

Rituximab

T-Cell Acute Lymphoblastic Leukemia

Explore 76 assets in T-Cell Acute Lymphoblastic Leukemia →
Floatz Rating
BB64/100
Confidence
Indicative
v0.2
Sponsor
University of Washington
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT06738368CT.gov
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
—Recruiting———
NCT05032183CT.gov
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
—Terminated———
NCT04318678CT.gov
CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
—Recruiting———
NCT03808610CT.gov
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
—Terminated———
NCT02538926CT.gov
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
—Withdrawn———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · T-Cell Acute Lymphoblastic Leukemia

AssetSponsorPhaseRating
Rituximab (this asset)University of WashingtonP2BB · 64
Vincristine SulfateChildren's Oncology GroupP3BB
DaunomycinSWOG Cancer Research NetworkP3BB
PegaspargaseChildren's Oncology GroupP3BB
Mercaptopurine AnhydrousSWOG Cancer Research NetworkP3BB
CrisantaspaseUniversity of WashingtonP3BB
PrednisoneChildren's Oncology GroupP3BB
AdriamycinSWOG Cancer Research NetworkP3BB
CytarabineSWOG Cancer Research NetworkP3BB

+42 more in the T-Cell Acute Lymphoblastic Leukemia cohort

Other indications for Rituximab

IndicationSponsorPhaseRating
Lymphoblastic Lymphoma—P4BBB · 75
Grade III Lymphomatoid Granulomatosis—P2BBB · 74
Testicular Lymphoma—P2BBB · 74

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Rituximab in T-Cell Acute Lymphoblastic Leukemia. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/immunoglobulin-g-1-human-mouse-monoclonal-idec-c2b8-gamma1-chain-anti-human-antigen-cd-20-disulfide-with-human-mouse-monoclonal-idec-c2b8-kappa-chain-dimer-t-cell-acute-lymphoblastic-leukemia

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →